A Phase III Study of Risk Directed Therapy for Infants With Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition (CEP-701, Lestaurtinib; IND 76431; NSC 617807)
Latest Information Update: 22 Jul 2024
At a glance
- Drugs Lestaurtinib (Primary) ; Asparaginase; Asparaginase; Asparaginase; Cyclophosphamide; Cytarabine; Cytarabine; Daunorubicin; Dexamethasone; Dexamethasone; Etoposide; Filgrastim; Filgrastim; Folinic acid; Hydrocortisone; Mercaptopurine; Methotrexate; Methotrexate; Methotrexate; Methylprednisolone; Pegaspargase; Prednisone; Vincristine
- Indications Acute biphenotypic leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Therapeutic Use
- 15 Jul 2024 Status changed from active, no longer recruiting to completed.
- 09 Aug 2023 Planned End Date changed from 20 Jul 2023 to 28 Jun 2024.
- 17 Aug 2022 Planned End Date changed from 1 Sep 2018 to 20 Jul 2023.